share_log

復宏漢霖:自願公告 -HLX22(重組人源化抗HER2單克隆抗體注射液)聯合曲妥珠單抗和化療(XELOX)對比曲妥珠單抗和化療(XELOX)聯合或不聯合帕博利珠單抗一線治療局部晚期或轉移性胃食管交界部和胃癌的國際多中心3期臨床研究於中國境內完成首例患者給藥

HENLIUS: VOLUNTARY ANNOUNCEMENT -THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONALMULTI-CENTER PHASE 3 CLINICAL STUDY OF HLX22(RECOMBINANT HUMANIZED ANTI-HER2 MONOCLONALANTIBODY INJECTION) IN COMBINATION WITH TRASTUZUMABAND CHEMOTHERAPY (XELOX) VERSUS TRASTUZUMA

HKEX ·  Nov 22 17:30
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more